What Infinite Biomedical Technologies does

Infinite Biomedical Technologies, LLC is a Baltimore, Maryland-based medical device company founded in 1997 that originated from the Johns Hopkins School of Medicine with a stated mission of translating laboratory research into clinical solutions for patients with upper limb loss. The company designs and manufactures prosthetic control hardware — most prominently the Glide myoelectric directional control system — which uses 2 to 8 electrodes to position a cursor on a configurable "Glide map" and enable precise directional control of multi-degree-of-freedom prosthetic hands, wrists, and elbows without requiring daily at-home maintenance. Its second product line, FlexCell, is an ultra-thin (sub-4mm) flexible lithium-polymer battery with magnetic charging and a 7.4VDC output, engineered specifically for upper-limb prosthetic integration and available in standard (31g) and mini (17g) variants. Supporting items include electrodes, accessories, the Glide Evaluation Kit (a 2-week loaner program that lets clinicians trial the system with patients), and the IBT Control App on iOS for remote configuration and performance monitoring. The company's intellectual property portfolio includes 9 accrued patents and 50+ peer-reviewed publications, and its devices are FDA Class 1 and Class 2 registered and CE marked, enabling distribution in 21 countries and serving more than 5,000 patients cumulatively.

IBT sells directly to prosthetists and clinicians through an enterprise field-sales motion that begins with an evaluation kit loan and progresses to outright hardware sales of the Glide system, FlexCell batteries, and electrodes. There is no consumer-direct channel, no subscription software layer, and no disclosed pricing, but the 2-week loan program with $100/day late fees indicates an embedded rental/equipment-trial component that resembles medical capital equipment distribution rather than high-velocity medical consumables. The company has funded itself entirely through government grants from the NIH (since founding), DARPA, and NSF — 55 awarded grants in total — without external equity or debt financing. Management consists of co-founders Nitish Thakor (Professor of Biomedical Engineering at Johns Hopkins) and Ananth Natarajan (former CEO for over ten years), supported by current CEO Rahul Kaliki, COO Dan Schlattman, and CTO Damini Argawal, alongside an engineering team of roughly 11–50 employees, several of whom hold degrees from Johns Hopkins.

Name

Infinite Biomedical Technologies

Legal name

Infinite Biomedical Technologies, LLC

Website

https://i-biomed.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Infinite Biomedical Technologies is a Baltimore-based medical device company that develops myoelectric directional control systems and flexible batteries for upper limb prosthetics, serving prosthetists, clinicians, and individuals with upper limb loss across 21 countries.

Ownership category

akta.pro rank

Product category

Upper Limb Myoelectric Prosthetic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems) (HLAHAEAH)

akta.pro secondary industries

Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets) (HLAHAMAD), Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN), Assistive & Accessibility Input Devices (Switches, Adaptive Controllers, Braille Keyboards) (HDACAFAL)

Keywords

• Myoelectric prosthetic control
• Upper limb prosthetics
• Flexible medical batteries
• Prosthetic control systems
• Directional electrode control

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: IBT generates revenue from selling proprietary medical devices including the Glide myoelectric control system and FlexCell flexible battery system, along with electrodes and accessories.
2. Evaluation Kit Loans: IBT loans Glide Evaluation Kits to clinicians for patient evaluation purposes, with a 2-week loan period and late fees for extended returns.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Infinite Biomedical Technologies designs, manufactures, and sells proprietary medical devices that enable control of myoelectric upper-limb prostheses. Its core commercial offerings are the Glide directional control system (which uses 2–8 electrodes to drive multi-degree-of-freedom hands, wrists, and elbows through a customizable Glide map) and the FlexCell ultra-thin flexible lithium-polymer battery system engineered specifically for prosthetic applications. The company supports its devices with the IBT Control App for iOS and a clinician-facing evaluation kit loaner program, and its products are FDA Class 1/Class 2 registered and CE marked for distribution across 21 countries.

Product overview

Infinite Biomedical Technologies offers a portfolio of two core products for upper limb prosthetics: Glide, a myoelectric directional control system that enables users to control multiple degree-of-freedom prosthetic devices through electrode-based cursor mapping, and FlexCell, a flexible lithium-polymer battery system with magnetic charging designed for prosthetic integration. The company also provides a Glide Evaluation Kit for clinical trials. IBT's technologies are FDA Class 1 and Class 2 registered and CE marked for international distribution across 21 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Glide: Myoelectric directional control system for upper limb prostheses, enabling precise directional control using 2 to 8 electrodes to control hands, wrists, and elbows.
• FlexCell

Products and services

• Glide Myoelectric directional control system for upper-limb prostheses that uses 2–8 electrodes to enable precise directional control of multiple degree-of-freedom prosthetic devices; designed for prosthetists and clinicians fitting transradial and transhumeral amputees with hands, wrists, and elbows from major terminal device brands.
• FlexCell Flexible lithium-polymer battery system engineered for individuals with upper-limb differences; ultra-thin (less than 4mm thick), magnetically charged, with 7.4VDC output and available in standard (31g) and mini (17g) variants with a 2-year expected service life, for use by prosthetists integrating power into upper-limb sockets.
• Glide Evaluation Kit Loaner kit allowing clinicians and patients to trial the Glide system before purchase; pre-configurable based on patient amputation level, side, and terminal device, with a standard 2-week loan period and $100/day late fee for extended returns; targeted at prosthetists evaluating Glide for clinical adoption.

Quantifiable outcome

• 5,000+ patients served with their technologies
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Johns Hopkins UniversitycoreStrategic or Co-development PartnerIBT originated from the Johns Hopkins School of Medicine in 1997. Co-founders Professor Nitish Thakor (Professor of Biomedical Engineering) and Dr. Ananth Natarajan established the company through this academic affiliation. Many team members have degrees from Johns Hopkins University.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Ottobock: Global leader in prosthetics and myoelectric control systems (including bebionic hand and various electrode systems). Directly competes with IBT's Glide in upper-limb prosthetic control, but at much broader portfolio and scale.
• Össur: Major prosthetic device manufacturer offering upper-limb solutions including the i-Limb hand. Comparable as a competitor in the upper-limb prosthetics space, with broader lower-limb and bracing lines giving it greater scale.

Direct peers

• Coapt: Specialist in myoelectric pattern-recognition control systems for upper-limb prostheses. Closest direct competitor to IBT's Glide, differentiated by an AI/ML control architecture rather than directional mapping.
• Fillauer Companies: Manufacturer of prosthetic components including terminal devices, electrodes, and controllers for upper-limb amputees. Comparable product overlap in prosthetic components and clinical sales motion to prosthetists.
• Steeper Group: UK-based prosthetics manufacturer offering myoelectric hands, electrodes, and control systems. Comparable in targeting prosthetists with upper-limb control hardware, with similar size and product scope to IBT.
• Touch Bionics (Össur): Original developer of the i-Limb quantum prosthetic hand (now under Össur). Directly comparable as a competitor in advanced upper-limb prosthetic terminal devices paired with proprietary control electronics.

Emerging players

• Mobius Bionics: Developer of the LUKE bionic arm, an advanced upper-limb prosthetic system with novel control schemes. Comparable as a niche player pursuing next-generation upper-limb control, though with a heavier hardware focus than IBT.
• BrainRobotics: Developer of AI-enabled myoelectric prosthetic hands targeting upper-limb amputees. Comparable in combining machine-learning control with prosthetic hands, competing for the same prosthetist channel as Glide.
• Open Bionics: Developer of 3D-printed bionic arms (Hero Arm) with multi-grip myoelectric control. Comparable in serving upper-limb amputees with electronic prosthetic control, though focused on lower-cost 3D-printed hardware.

Others

• SynTouch: Developer of tactile-sensing and sensory-feedback technologies for prosthetic and robotic applications. Comparable as an adjacent technology provider in the upper-limb prosthetic research ecosystem, with potential to integrate with IBT's control stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/InfiniteBiomed
• Facebookfacebook.com/InfiniteBiomed
• LinkedInlinkedin.com/company/infinite-biomedical-technologies
• Instagraminstagram.com/infinite_biomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infinite Biomedical Technologies